Adicet Bio, Inc. (ACET)
NASDAQ: ACET · IEX Real-Time Price · USD
1.950
-0.075 (-3.70%)
At close: Apr 19, 2024, 4:00 PM
2.040
+0.090 (4.62%)
After-hours: Apr 19, 2024, 7:37 PM EDT
Adicet Bio Stock Forecast
ACET's stock price has decreased by -68.19% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Adicet Bio stock have an average target of 13.86, with a low estimate of 5.00 and a high estimate of 27. The average target predicts an increase of 610.77% from the current stock price of 1.95.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Adicet Bio stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +412.82% | Apr 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +412.82% | Mar 20, 2024 |
| Wedbush | Wedbush | Buy Reiterates $5 | Buy | Reiterates | $5 | +156.41% | Mar 20, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +874.36% | Mar 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $26 → $10 | Strong Buy | Maintains | $26 → $10 | +412.82% | Feb 2, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.90
from -3.31
EPS Next Year
-1.91
from -1.90
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 207.2M | 325.8M |
| Avg | n/a | n/a | n/a | 105.5M | 209.9M |
| Low | n/a | n/a | n/a | 41.1M | 96.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 208.9% |
| Avg | - | - | - | - | 99.0% |
| Low | - | - | - | - | -8.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.14 | -1.10 | -0.92 | -1.47 | -0.74 |
| Avg | -1.90 | -1.91 | -1.97 | -1.43 | -0.71 |
| Low | -2.99 | -3.34 | -3.91 | -1.37 | -0.69 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.